Phosphorylated tau (P‐tau) in CSF is an established AD biomarker that is seemingly specific for Alzheimer's disease (AD). Several recent papers also show highly promising results for plasma P‐tau, with a clear increase in AD, also in the very early phases of the disease. Further, ...
Plasma p-tau231 showed more robust associations with PET biomarkers than p-tau181 in pre-symptomatic individuals. The combination of p-tau and Aβ42/40 biomarkers detected early AD pathology and cognitive decline. Such markers could be used as pre-screening tools to reduce the ...
However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals ...
Plasma p-tau217 has emerged as the most promising blood-based marker (BBM) for the detection of Alzheimer Disease (AD) pathology, yet few studies have evaluated plasma p-tau217 performance in memory clinic settings. We examined the performance of plasma p-tau217 for the detection of AD using...
Phosphorylated tau (p-tau) and amyloid beta (Aβ) in human plasma may provide an affordable and minimally invasive method to evaluate Alzheimer’s disease (AD) pathophysiology. The medial temporal lobe (MTL) is susceptible to changes in structural integr
(Simoa) measurements of plasma P-tau181, total tau, amyloid beta (Aβ)40 and Aβ42, as well as derived ratios were correlated with neuroimaging modalities indicating brain amyloid (Aβ+), hippocampal atrophy, and CeVD in a Singapore-based cohort of non-cognitively impaired (NCI; n=43),...
Phosphorylated tau (p-tau) and amyloid beta (Aβ) in human plasma may provide an affordable and minimally invasive method to evaluate Alzheimer’s disease (AD) pathophysiology. The medial temporal lobe (MTL) is susceptible to changes in structural integr
doi:10.1002/alz.047539Juan Lantero RodriguezThomas K KarikariMarc Suárez-CalvetClaire TroakesAndrew KingAndreja EmeriDag AarslandAbdul HyeHenrik ZetterbergKaj BlennowJohn Wiley & Sons, LtdAlzheimer's & Dementia
Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both amyloid and tau pathology in clinical settings, but their performance in heterogeneous community-based populations is unclear. We examined P-tau181 and P-tau217 (n = 1,329, aged 30–98 years), in...
In AD context, p-tau biomarkers that work in blood must also have high (if not better) diagnostic and predictive performances in CSF, due to the close contact of the CSF with the brain parenchyma and serving as a sink for brain extracellular solutes [22]. P-tau biomarker performances in ...